Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has delivered a dividend-adjusted total return of roughly 347% over the last five ...

To get a price/earnings-to-growth (PEG) ratio of 1.0, that would therefore imply a fair value of $730 for Lilly stock -- and right now, Lilly stock costs only $640 and change!

With its 2-star rating, we believe Eli Lilly’s stock is overvalued compared with our long-term fair value estimate of $650 per share. In aggregate, the company looks well positioned to drive top ...

Weaker-than-expected guidance sent the stock price down significantly. Even so, Lilly grew revenue by 45% year over year to $12.7 billion.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

Eli Lilly stock is up 6.6% today and 50% for the year. Driving those gains is excitement over two potential blockbusters—one for obesity and diabetes and another for Alzheimer’s.